Gilead Sciences, Inc. $GILD Shares Sold by DMC Group LLC

DMC Group LLC reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.4% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 13,977 shares of the biopharmaceutical company’s stock after selling 497 shares during the quarter. Gilead Sciences accounts for 1.2% of DMC Group LLC’s portfolio, making the stock its 21st largest position. DMC Group LLC’s holdings in Gilead Sciences were worth $1,550,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Smallwood Wealth Investment Management LLC acquired a new position in shares of Gilead Sciences in the 1st quarter worth approximately $25,000. Activest Wealth Management lifted its holdings in shares of Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the last quarter. Goodman Advisory Group LLC acquired a new position in shares of Gilead Sciences in the 1st quarter worth approximately $29,000. Colonial Trust Advisors increased its stake in Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 213 shares during the period. Finally, Core Alternative Capital increased its stake in Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 241 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

GILD has been the topic of several recent research reports. Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price on the stock in a research note on Tuesday, August 19th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research note on Saturday, September 27th. Rothschild & Co Redburn upped their target price on shares of Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Finally, Needham & Company LLC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective on the stock in a research report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $117.17.

Gilead Sciences Trading Up 2.8%

NASDAQ GILD opened at $116.78 on Wednesday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The firm’s fifty day moving average price is $114.41 and its 200 day moving average price is $110.06. The company has a market capitalization of $144.90 billion, a price-to-earnings ratio of 23.26, a price-to-earnings-growth ratio of 0.77 and a beta of 0.34. Gilead Sciences, Inc. has a 12 month low of $84.17 and a 12 month high of $121.83.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s revenue was up 1.4% on a year-over-year basis. During the same period last year, the firm posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is 62.95%.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Monday, July 28th. The shares were sold at an average price of $113.94, for a total value of $1,139,400.00. Following the transaction, the chief executive officer directly owned 605,725 shares of the company’s stock, valued at $69,016,306.50. This trade represents a 1.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $283,925.00. Following the sale, the chief financial officer owned 159,555 shares of the company’s stock, valued at approximately $18,120,661.35. This represents a 1.54% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 82,000 shares of company stock valued at $9,402,130. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.